For the first time in India, couples seeking In Vitro Fertilisation (IVF) treatment for conception can rely on a globally preferred, automated egg-freezi...
Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-D...
A new survey-based Genomics Tracker focused on the EU-5 (France, Germany, Italy, Spain, and the United Kingdom) by DeciBio Consulting LLC provides update...
-Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medi...
Funding led by Eos Advisory and Midlands Engine Investment Fund II, through appointed fund manager Mercia Ventures, signals strong investor confidenc...
Elecoglipron demonstrated a favorable safety and tolerability profile in Chinese adults living with obesity/overweight with or without type 2 diabete...
Wellumio, a New Zealand-based medical technology company developing a portable neuroimaging device for rapid, point-of-care stroke detection, has raised $7...
MerryLife Biomedical Inc., a clinical-stage biotechnology company focused on neurodegenerative diseases, announced positive Phase 1 results for TML-6, it...
In OCEANIC-STROKE, patients who received asundexian after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack were significant...
Rare Patient Voice’s 200,000+ registered patients and caregivers expand Konovo’s ability to deliver connected insights across a broad range o...
Cloud-based AI application for colorectal cancer prevention: Enhancing detection of clinically significant lesions without compromising safety and workfl...
Agreement Expands Access to Evonik's CARE Brand Medical Grades in the U.S. and Canada Formerra, a leader in performance materials distribution, to...
Diffuse Bio, a leading provider of AI and experimental platforms for designing and screening protein therapeutics, announced significant enhancements to ...
Company expects to receive a negative opinion following oral explanation feedback and intends to request re‑examination upon review of formal adoptio...
© 2026 Biopharma Boardroom. All Rights Reserved.
